Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. Journal Of Clinical Oncology 2024, 42: e15625-e15625. DOI: 10.1200/jco.2024.42.16_suppl.e15625.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNARecurrence-free survivalColorectal cancerMRD assaysDetection of molecular residual diseaseLevels of circulating tumor DNAPoor recurrence-free survivalTreated with curative intentDetect circulating tumor DNAProspective cohort of patientsCurative interventionsCurative-intent treatmentCohort of patientsSingle nucleotide variantsStage I-IIISeparation of patientsMRD- patientsMRD testingNeoadjuvant treatmentResidual diseaseClinical recurrenceCurative intentRectal cancerTumor DNAUltra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.
Nixon A, Navarro F, Zhou K, Abbott C, Howard L, Brady J, Liu Y, Jia J, Niedzwiecki D, Chen R, Strickler J, Boyle S, Uronis H. Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer. Journal Of Clinical Oncology 2024, 42: 4025-4025. DOI: 10.1200/jco.2024.42.16_suppl.4025.Peer-Reviewed Original ResearchMetastatic esophagogastric cancerMolecular residual diseaseImmune checkpoint blockadeProgression-free survivalCtDNA dynamicsCtDNA levelsHigher hazard ratioOverall survivalDetection of molecular residual diseasePhase II study of pembrolizumabSingle-arm phase II studyWhole-genome sequencingSingle nucleotide variantsMolecular progressionResponse rateStudy of pembrolizumabBaseline prior to treatmentUnivariate Cox regression analysisCox regression analysisFFPE tumor samplesOverall response rateMedian lead timeImprove treatment decision-makingLong-term survivalLiquid biopsy platform